240 related articles for article (PubMed ID: 28883726)
1. Doxorubicin-loaded redox-responsive micelles based on dextran and indomethacin for resistant breast cancer.
Zhou Y; Wang S; Ying X; Wang Y; Geng P; Deng A; Yu Z
Int J Nanomedicine; 2017; 12():6153-6168. PubMed ID: 28883726
[TBL] [Abstract][Full Text] [Related]
2. Chemosensitizing indomethacin-conjugated dextran-based micelles for effective delivery of paclitaxel in resistant breast cancer therapy.
Ji W; Wang B; Fan Q; Xu C; He Y; Chen Y
PLoS One; 2017; 12(7):e0180037. PubMed ID: 28686704
[TBL] [Abstract][Full Text] [Related]
3. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.
Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z
ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761
[TBL] [Abstract][Full Text] [Related]
4. Indomethacin-grafted and pH-sensitive dextran micelles for overcoming inflammation-mediated multidrug resistance in breast cancer.
Zeng X; Cheng X; Zheng Y; Yan G; Wang X; Wang J; Tang R
Carbohydr Polym; 2020 Jun; 237():116139. PubMed ID: 32241443
[TBL] [Abstract][Full Text] [Related]
5. Redox-responsive polymer-drug conjugates based on doxorubicin and chitosan oligosaccharide-g-stearic acid for cancer therapy.
Su Y; Hu Y; Du Y; Huang X; He J; You J; Yuan H; Hu F
Mol Pharm; 2015 Apr; 12(4):1193-202. PubMed ID: 25751168
[TBL] [Abstract][Full Text] [Related]
6. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice.
Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD
Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307
[TBL] [Abstract][Full Text] [Related]
7. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F
Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118
[TBL] [Abstract][Full Text] [Related]
8. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
[TBL] [Abstract][Full Text] [Related]
9. Redox-Responsive Polyphosphoester-Based Micellar Nanomedicines for Overriding Chemoresistance in Breast Cancer Cells.
Ma YC; Wang JX; Tao W; Sun CY; Wang YC; Li DD; Fan F; Qian HS; Yang XZ
ACS Appl Mater Interfaces; 2015 Dec; 7(47):26315-25. PubMed ID: 26552849
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin derivative loaded acetal-PEG-PCCL micelles for overcoming multidrug resistance in MCF-7/ADR cells.
Zhong XC; Xu WH; Wang ZT; Guo WW; Chen JJ; Guo NN; Wang TT; Lin MT; Zhang ZT; Lu YY; Yang QY; Han M; Xu DH; Gao JQ
Drug Dev Ind Pharm; 2019 Sep; 45(9):1556-1564. PubMed ID: 31271317
[No Abstract] [Full Text] [Related]
11. Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers.
Huang W; Lang Y; Hakeem A; Lei Y; Gan L; Yang X
Int J Nanomedicine; 2018; 13():1723-1736. PubMed ID: 29606866
[TBL] [Abstract][Full Text] [Related]
12. Redox-responsive nanoparticles from the single disulfide bond-bridged block copolymer as drug carriers for overcoming multidrug resistance in cancer cells.
Wang YC; Wang F; Sun TM; Wang J
Bioconjug Chem; 2011 Oct; 22(10):1939-45. PubMed ID: 21866903
[TBL] [Abstract][Full Text] [Related]
13. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin.
Qiu L; Qiao M; Chen Q; Tian C; Long M; Wang M; Li Z; Hu W; Li G; Cheng L; Cheng L; Hu H; Zhao X; Chen D
Biomaterials; 2014 Dec; 35(37):9877-9887. PubMed ID: 25201738
[TBL] [Abstract][Full Text] [Related]
14. Shell-sheddable micelles based on dextran-SS-poly(epsilon-caprolactone) diblock copolymer for efficient intracellular release of doxorubicin.
Sun H; Guo B; Li X; Cheng R; Meng F; Liu H; Zhong Z
Biomacromolecules; 2010 Apr; 11(4):848-54. PubMed ID: 20205476
[TBL] [Abstract][Full Text] [Related]
15. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.
Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G
J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819
[TBL] [Abstract][Full Text] [Related]
16. Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor.
Chen Y; Zhang W; Huang Y; Gao F; Sha X; Fang X
Int J Pharm; 2015 Jul; 488(1-2):44-58. PubMed ID: 25899286
[TBL] [Abstract][Full Text] [Related]
17. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
18. Indomethacin-based stimuli-responsive micelles combined with paclitaxel to overcome multidrug resistance.
Wang S; Tan X; Li S; Zhou Y; Geng P; Hua A; Deng A; Yu Z
Oncotarget; 2017 Dec; 8(67):111281-111294. PubMed ID: 29340053
[TBL] [Abstract][Full Text] [Related]
19. Redox-Responsive Amphipathic Dextran Nanomicelles for Solid Tumor Therapy.
Song Y; Lou B; Cheng J; Zhao P; Lin C; Wen X
J Biomed Nanotechnol; 2016 Dec; 12(12):2083-96. PubMed ID: 29368837
[TBL] [Abstract][Full Text] [Related]
20. A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.
Song Q; Chuan X; Chen B; He B; Zhang H; Dai W; Wang X; Zhang Q
Drug Deliv; 2016 Jun; 23(5):1734-46. PubMed ID: 25853477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
